论文部分内容阅读
旅行者主要通过接种疫苗预防甲型肝炎(HA),尤其在高度发达的国家,所有旅行者都要免疫接种。由于新的高效HA灭活疫苗价格昂贵,因此需要对HA的预防对策进行反复评估。为此,作者对目前以色列的旅行者进行了抗-HVA流行率调查,并从经济上探讨了免疫接种前筛选抗-HAV IgG的可行性。 研究对象为389名以色列旅行者,男性54％,女性46％,平均年龄39.5(22～74)
Travelers primarily prevent hepatitis A through vaccination, especially in highly developed countries where all travelers are immunized. Due to the high cost of the new high-efficiency HA inactivated vaccine, there is a need to repeatedly evaluate HA’s preventive strategies. To this end, the authors conducted a survey of current anti-HVA prevalence rates among Israeli travelers and economically explored the feasibility of screening anti-HAV IgG prior to immunization. The study population was 389 Israeli travelers, 54% males and 46% females, with an average age of 39.5 (range 22-74)